4.4 Article

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

期刊

CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 54, 期 6, 页码 487-496

出版社

SPRINGER
DOI: 10.1007/s00280-004-0835-9

关键词

9-nitrocamptothecin; 9-aminocamptothecin; oral administration; pharmacokinetics

资金

  1. NCI NIH HHS [2P30 CA47904] Funding Source: Medline
  2. NCRR NIH HHS [5M01RR00056] Funding Source: Medline

向作者/读者索取更多资源

Purpose: Oral administration of 9-nitrocamptothecin (9NC), and the formation of its metabolite 9-aminocamptothecin (9AC), may be associated with high interpatient and intrapatient variability. Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part of phase I and phase II studies. Experimental design: In phase I schedule A, 9NC was administered orally daily for 5 days per week for 2 weeks repeated every 4 weeks. On phase I schedule B, 9NC was administered daily for 14 days repeated every 4 weeks. In Phase II, 9NC was administered daily for 5 days during 8 weeks ( one cycle). Serial blood samples were obtained on day 1 and day 10 or 11 for phase I studies, and day 1 and day 50 for the phase II study. Recovery of 9NC and 9AC in urine was evaluated on day 1 and day 10 or 11 in the phase I study. Area under the 9NC and 9AC plasma concentration vs time curves from 0 to 24 h (AUC(0 - 24 h)) were calculated using compartmental analysis. Results: The mean +/- SD 9NC lactone AUC(0 24) (h) values on day 1 at the maximum tolerated dose of schedules A and B (2.43 and 1.70 mg/m(2), respectively) and the phase II dose (1.5 mg/m(2)) were 78.9 +/- 54.4, 155.7 +/- 112.8, and 48.3 +/- 17.5 ng/ ml.h, respectively. The mean +/- SD 9AC lactone AUC(0 -24 h) values at these same doses of 9NC were 17.3 +/- 17.9, 41.3 +/- 16.6, and 31.3 +/- 12.8 ng/ml h, respectively. The ratios of 9NC lactone AUC0 - 24 h on day 10 or 11 to day 1 on phase I A and B were 1.27 +/- 0.68 and 1.73 +/- 1.56, respectively, and the ratios 9AC lactone AUC0 - 24 h on day 10 or 11 to day 1 on phase I A and B were 2.23 +/- 1.02 and 1.65 +/- 0.97, respectively. The recovery of 9NC and 9AC in the urine was < 15%. Conclusions: There was significant interpatient and intrapatient variability in the disposition of 9NC and 9AC. 9NC and 9AC undergo primarily nonrenal elimination.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据